Survodutide: Side Effects & Safety
Part of the Survodutide Complete Guide
Research Peptides
We may earn a commission if you purchase through this link, at no extra cost to you.
Overall Safety Profile
Survodutide's side effect profile is consistent with the GLP-1 agonist class, with higher rates of GI events than some comparators. The glucagon component adds modest cardiovascular effects requiring monitoring.
Reported Side Effects
- Nausea (40–60%): Higher rates than some GLP-1 agonists
- Vomiting and diarrhea: Common
- Decreased appetite: Therapeutic but can be excessive
- Heart rate increase: Mild, glucagon-related
- ALT elevations: Transient liver enzyme increases in some patients
Important Limitations
Phase 3 data not yet available. Long-term safety beyond 48 weeks unknown. The higher GI event rates may limit tolerability compared to better-tolerated alternatives. Not yet approved for any indication.
Potential Contraindications
- Personal/family history of MTC or MEN2
- Severe hepatic impairment
- Pregnancy and breastfeeding